Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib
- Development stage
- Approved
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lenvatinib is an oral small molecule receptor tyrosine kinase inhibitor developed for the treatment of various cancers. It inhibits multiple targets involved in tumor angiogenesis and cancer progression, including vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1–4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET proto-oncogene. By blocking these kinases, lenvatinib disrupts signaling pathways that promote tumor cell proliferation and new blood vessel formation. Lenvatinib is approved for use as monotherapy or in combination with other agents to treat differentiated thyroid cancer refractory to radioactive iodine therapy, advanced renal cell carcinoma (with everolimus or pembrolizumab), unresectable hepatocellular carcinoma, endometrial carcinoma (with pembrolizumab), and unresectable thymic carcinoma in some regions.
- Brand names
- LenvimaKisplyx
- Other names
- lenvatinib mesylate
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib.